Learn everything you need to know about Trastuzumab-pronunciation ... every 3 weeks or once a week along with other chemotherapy medications, and then once every 3 weeks after treatment.

Trastuzumab emtansine is recommended, within its marketing authorisation, as an option for treating human epidermal growth factor receptor 2 (HER2)‑positive, unresectable, locally advanced or ...

Trastuzumab was discontinued because of cardiac dysfunction in 15.6% of patients. Age >50 years, prescription of antihypertensive medication, and post-anthracycline LVEF values of 50–54% (0.50 ...

Evidence-based recommendations on trastuzumab emtansine (Kadcyla) for human epidermal growth factor receptor 2 (HER2)‑positive, unresectable, locally advanced or metastatic breast cancer in adults who ...